Tirzepatide
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 414
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Tirzepatide High Dose 1 | n/r | n/r | n/r | n/r |
| Tirzepatide High Dose 2 | n/r | n/r | n/r | n/r |
| Tirzepatide | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
Not shown
- Tirzepatide High Dose 1: endpoint not reported
- Tirzepatide High Dose 2: endpoint not reported
- Tirzepatide: endpoint not reported
- Placebo: endpoint not reported